Rui-lan Gao

Rui-lan Gao

The First Affi liated Hospital of Zhejiang Chinese Medical University, China

Title: Research and development of the effective components of Panaxdiol saponin as new Chinese patent medicine for treating hemocytopenia


Rui-lan Gao has completed master degree at the age of 30 years from Zhejiang Medical University in China and completed postdoctoral studies from University of New South Wales in Australia. Now she is a Professor in Hematology, Head of Hematology Research Institution in The First Affiliated Hospital of Zhejiang Chinese Medical University in China. She has published more than 60 papers in journals. She is a vice Chairwoman of Hematology Committee of the National Integrative Medicine Association in China, and a Chairwoman of Hematology Committee of the Zhejiang Provincial Association of Integrative Medicine. She is a team leader of the project “Research and development panaxdiol saponin as new Chinese patent medicine”.





At present, pancytopenia (hemocytopenia) such as primary immune thrombocytopenia (ITP), aplastic anemia and agnogenic leukocytopenia were oft en treated by glucocorticoids, androgen or immunosuppressive agents, but the response to these treatments has not been always satisfactory. Besides they may cause serious side eff ects. Our research has identifi ed a biological active component, panaxadiol saponins components (PDS-C) isolated from Chinese ginseng extract, and formulated into capsules. Th e composition and content of PDS-C have been defi ned 92.44% in purity by HPLC-UV-ESI-MS and HPLC using specifi c monomers of ginsenosides as reference standards. PDS-C is very effi cacious for treating mice and rats with ITP and aplastic anemia, and myelosuppression caused by chemotherapy or radiation. Our animal model studies and cell biology and molecular biology experiments demonstrated that PDS-C possessed dual activities, namely that of promoting proliferation and diff erentiation of hematopoietic progenitor cells, and that of regulating the immune function. We successfully obtained approval from SFDA in 2010 to conduct clinical trials of PDS as class-fi ve new Chinese patent medicine. Phase II clinical trials of PDS-C were carried out in treatment of ITP and agnogenic leukocytopenia. PDS-C as a new Chinese patent medicine has been successfully transferred to industry for its commercialization. We believe that PDS-C is eff ective and safe in the treatment of refractory hemocytopenia. Th e advantages are: eff ective in small doses, convenient to use because of its oral administration, its lack of side eff ects, it could be used alone or in combination with pharmacological agents, which improve the effi cacy and decrease side eff ects.

Speaker Presentations

Speaker PDFs